Foundation Medicine Public Company Parent: Roche

Foundation Medicine, Inc. is a public American company which develops, manufactures and sells genomic analysis diagnostics for solid and circulating cancers. The company's tests are based on next-generation sequencing technology. The company's clinical assays, FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies and sarcomas, provide a comprehensive genomic profile to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. In addition to its majority shareholder Roche, Foundation Medicine also has business agreements with Pfizer, Johnson & Johnson and Novartis, and two thirds of its revenue comes from pharmaceutical company partnerships.

Funding 💰

Select investors Roche Venture Fund, Kleiner Perkins, Third Rock Ventures, GV, Bill Gates, Deerfield Management, Casdin Capital, Redmile Group
Last update: May 8, 2018